Skip to content
Artwork for The Longevity Podcast: Alzheimer's and Brain Health Research
Health & FitnessMedicineScienceLife Sciences

The Longevity Podcast: Alzheimer's and Brain Health Research

Dung Trinh

AI-hosted deep dives into the latest Alzheimer's, dementia and brain health research, curated by Dr. Dung Trinh. Each episode breaks down a recent study or topic, such as diet, sleep, exercise, heart health, biomarkers, early detection and new treatments. We explain what the science says and what it may mean for staying sharp as we age.

Episodes are discussions generated with AI hosts. Every episode cites its sources so you can read the original research yourself. This podcast is for education only and is not medical advice. Talk with your doctor about your own health.

Play
  • 67 episodes
  • Avg 31 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • October 17 · 1 hr 4 min

    Loneliness and Stress Linked to Faster Aging on Epigenetic Clocks

    Send us Fan Mail Can loneliness, depression, and stress make your body age faster on the inside? Researchers pooled 22 studies of adults from midlife onward that measured "epigenetic age," a biological age estimated from DNA methylation patterns in blood. Greater loneliness, depression, and psychosocial stress were each linked to faster epigenetic aging, most consistently on newer clocks such as PhenoAge and GrimAge that track health and lifespan. The links were modest, and they show association rather than cause. The authors point out that no eligible studies looked at anxiety, that all included studies came from Western countries, and that trials are needed to see whether easing these burdens can slow biological aging. Source: Guo J, Shan J, Ye KX, Liang W, Wang Y, Ang ET, Lee TS, Suckling J, Maier AB, Feng L, Psychological adversities and epigenetic ageing in midlife and older age: A systematic review and meta-analysis, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100650 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 16 · 43 min

    When Does Cognitive Decline Begin? Big Study Points to Your 30s

    Send us Fan Mail At what age does measurable thinking decline actually begin? Researchers pooled long-term data on 14,389 adults aged 22 to 94 from three population studies in China, the United States, and the Czech Republic, putting different cognitive tests on a common 0 to 100 scale and following people for an average of seven to nine years. A small but detectable drop in overall cognition first showed up in the 31 to 40 age group and grew steadily larger with age. Non-memory skills such as attention and executive function showed change from about age 31, while significant memory decline appeared only after 50. Individual paths varied widely, so age alone did not predict who would decline. The authors say the findings support looking at midlife cognitive monitoring and a life-course approach to brain health, while noting the limits of combining different tests across cohorts. Source: Novotný JS, Klil-Drori S, Geda YE, Nasreddine Z, Stokin GB, Timing of cognitive decline onset and life-course trajectories: A pooled longitudinal analysis of 14,389 adults across three cohorts, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100649 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 15 · 41 min

    Brain's Fluid Factory: Choroid Plexus Size and Alzheimer's Pathology

    Send us Fan Mail The choroid plexus is the tissue inside the brain's ventricles that makes cerebrospinal fluid and helps clear waste. Earlier imaging studies found it grows larger across the Alzheimer's continuum, but few had checked that against autopsy, the gold standard for diagnosis. Toronto researchers used National Alzheimer's Coordinating Center data on 111 people who had a brain MRI within five years of death and a post-mortem exam. A larger choroid plexus, adjusted for head size, went along with intermediate and high levels of Alzheimer's pathology and with cognitive impairment, while women had smaller volumes than men. Among people with similar high pathology, those with more impairment tended to have larger volumes. The authors say longitudinal imaging and direct measures of fluid flow are needed to understand what drives these changes. Source: Fernandes F, Dey A, Ma A, et al., Choroid plexus volume in pathology-confirmed Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100648 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 14 · 49 min

    Dementia Agitation Care: Are Special Care Units Worth the Cost?

    Send us Fan Mail Special care units for people with dementia who have agitation and other behavioral symptoms offer a home-like setting with specialized staff. But are they worth the money? The European RECage study followed 508 people for three years across Italy, Switzerland, Germany, Norway, France, and Greece, comparing those cared for in these units with those who were not. Over three years, the special care unit group had slightly fewer quality-adjusted life years (about 0.13 fewer) and roughly €25,000 higher total costs, so the units were likely not cost-effective in this analysis. Because the study was observational and the results are uncertain, the authors say neither widespread rollout nor cutting these units can be recommended yet, and they call for a randomized study stratified by region. Source: Handels R, Michalowsky B, Mendes A, et al., Cost-effectiveness of the special care unit for persons with dementia, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100647 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 13 · 59 min

    Cognitive Decline Prediction: Why MRI Models Fail Across Cohorts

    Send us Fan Mail Machine learning can forecast how fast thinking skills will slip — but how well do those models work on a new group of patients? Researchers in Zurich trained models on ADNI (1,237 people) and OASIS-3 (662 people) to predict yearly change in CDR-SOB and MMSE scores. Adding structural MRI to clinical and demographic data improved predictions inside each dataset (R² up to about 0.41–0.42 for CDR-SOB). When the same models were tested on the other cohort, performance dropped (R² roughly 0.18–0.35). Slimming the models to only the top predictors did about as well externally, which points to redundant features rather than a free lunch. The paper argues that measuring this generalizability gap is essential before trusting these tools for individual planning. Source: Hüppi RM, Langer N, Vieira BH, Quantifying generalization error in machine learning prediction of cognitive decline, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100646 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 12 · 54 min

    Brain Health: Lopsided Memory Centers Signal Decline Without Amyloid

    Send us Fan Mail Can the shape of your brain's memory center reveal risk that amyloid tests miss? Researchers at UC Irvine studied MRI scans and up to 10 years of follow-up in 1,142 dementia-free older adults from the Alzheimer's Disease Neuroimaging Initiative. Smaller overall hippocampal volume tracked with worse thinking and faster decline in every area tested. But a bigger size difference between the left and right hippocampus was tied specifically to memory decline, and it predicted progression to dementia only in people without detectable amyloid. The authors suggest hippocampal asymmetry may flag brain changes that go beyond classic Alzheimer's pathology. Source: Ghanbarian E, et al., Hippocampal asymmetry captures non-amyloid-related risk of memory decline and clinical progression, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100638 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 11 · 24 min

    Can an Eye Exam Spot Alzheimer's? Retinal Blood Vessels Hold Clues

    Send us Fan Mail Could a routine eye exam one day flag Alzheimer's disease? Because the retina is an extension of the brain, this study used a genetic method called Mendelian randomization, drawing on large genetic datasets and more than 52,000 UK Biobank participants, to sort out which eye changes Alzheimer's actually causes. Genetic risk for Alzheimer's was linked to more twisted small arteries in the retina, with weaker hints of thinning in the inner retinal layers. An apparent link between optic disc size and Alzheimer's was probably explained by refractive error. The authors say more work is needed before eye screening for dementia is ready for the clinic. Source: Kiser H, et al., Can we identify people with Alzheimer's disease from examination of the eye? A bidirectional Mendelian randomization (MR) study, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100635 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 10 · 36 min

    Brain Health: Fluid Spaces on MRI Reveal Amyloid vs Vascular Damage

    Send us Fan Mail Enlarged perivascular spaces, the fluid-filled channels around small blood vessels in the brain, show up on routine MRI. This study of 307 people with cognitive impairment from a Seoul dementia cohort asked whether amyloid and blood vessel disease leave different patterns of these spaces. Vascular burden was linked to more enlarged spaces deep in the basal ganglia, regardless of amyloid. Amyloid and vascular disease were each linked to more spaces in the parietal, temporal, and occipital white matter, with no extra increase when both were present. The spatial pattern may help hint at which pathologies are driving cognitive impairment. This episode is an AI deep-dive overview of the open-access paper. It sticks to what the study reports. Source: Kim W, et al., Distinct spatial patterns of perivascular spaces enlargement for multiple and co-existing pathologies of cognitive impairment, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100631 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 8 · 30 min

    Dementia Stages: How a Daily Function Test Tells Mild From Moderate

    Send us Fan Mail How do clinicians tell mild dementia from moderate dementia? This study tested the Functional Activities Questionnaire, an informant-based checklist of everyday tasks, in more than 34,000 people from the US NACC database and confirmed the results in the ADNI and FTLDNI cohorts. A score of 18 or higher caught 96% of moderate dementia cases, while a cut-off of 23 traded a little sensitivity for higher specificity. Older age and lower cognitive scores made misclassification more likely. Source: Ersözlü E, et al., Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100630 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 7 · 32 min

    Alzheimer's Timeline: Amyloid to Tau Is Faster in Women, APOE4

    Send us Fan Mail Using amyloid and tau PET scans from two US cohorts, ADNI and the Harvard Aging Brain Study, researchers estimated how long it takes to go from amyloid positivity to tau positivity. That interval varied widely and was shorter in APOE4 carriers, women, and people who became amyloid positive at older ages. A shorter amyloid-to-tau interval predicted earlier symptom onset, pointing to a narrower window for early detection in these groups. Source: Milà-Alomà M, et al., The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100622 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 6 · 49 min

    Gut Molecule ImP Linked to Faster Alzheimer's Decline

    Send us Fan Mail A gut bacterial compound called imidazole propionate (ImP) is linked to Alzheimer's-related brain changes and faster cognitive decline in a large Wisconsin cohort, with mouse and cell studies pointing to barrier and tau pathways. Researchers measured blood ImP in nearly 1,200 mostly cognitively unimpaired adults, connected ImP-producing gut bacteria to disease markers, and found a genetic signal tied to both ImP levels and Alzheimer's risk. In mice, chronic ImP worsened Alzheimer-like pathology. This episode is an AI deep-dive overview of the open-access Nature Communications paper. It sticks to what the study reports. Source: Vemuganti V et al., Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology. Nat Commun. 2026. doi:10.1038/s41467-026-74744-z (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 5 · 37 min

    Alzheimer's Blood Proteins: How MRI Links Them to Risk

    Send us Fan Mail A Mendelian randomization study of plasma proteins, structural MRI measures, and Alzheimer's disease risk found 12 neuroimaging metrics and 1,633 proteins with causal ties to AD. Brain imaging also mediated about 67% of the link between the immune-related protein PTPRC and Alzheimer's risk across the disease course. Source: Xu X, et al., Bidirectional causal relationships between plasma proteins, neuroimaging metrics and risk of Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100619 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 4 · 46 min

    Dementia Safety Risks: Medication Errors Top China Study

    Send us Fan Mail A China-wide survey of 1,057 older adults with Alzheimer's or related cognitive impairment found 73.5% had at least one safety incident in the past year, and over a third reported three or more. Medication errors and verbal aggression were the most common, followed by falls and physical aggression. Medication errors and getting lost also sat at the center of how different incidents linked together across care settings and regions. Source: Zhou Y, et al., Mapping the nature, type, and association network of safety incidents among individuals with cognitive impairment in China: a large-scale multicenter cross-sectional study, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100606 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 3 · 19 min

    Alzheimer's Drug Safety: Why Blood Thinner Exclusions Matter

    Send us Fan Mail A letter in JPAD argues that a reported safety advantage for an anti-amyloid antibody drug, in a European-label subgroup of its phase 3 trial, may largely reflect excluding patients on blood thinners. About one in four people with Alzheimer's take those medicines in real-world data, so the subgroup findings may not apply in everyday practice. Source: Ijaz A, Mohyudin G, The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100628 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 2 · 19 min

    Dementia Risk Knowledge: Why Recognition Isn't Enough

    Send us Fan Mail A letter responds to a large review of public dementia risk awareness, arguing that recognizing a risk factor is not the same as knowing what to do about it. The authors urge surveys to measure actionable knowledge, whether risks are personal habits or policy problems, and to separate fear and stigma from true risk perception. Source: Xie Z, Su J, Liao T, Beyond recognition: Refining the assessment of public knowledge and risk perception in dementia prevention, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100602 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 1 · 21 min

    Donanemab EU Label: Why Subgroup Data Matter for Alzheimer's Drugs

    Send us Fan Mail When Europe approved donanemab and lecanemab, the label was narrower than the trials: early Alzheimer's, APOE ε4 non-carriers or heterozygotes, plus extra exclusions. This editorial walks through why EU-eligible subgroup analyses matter—and how Jessen's TRAILBLAZER-ALZ 2 re-analysis shows benefit and safety still hold (even improve a bit) in the patients clinicians actually treat. Source: Grimmer T, From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100665 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • September 30 · 21 min

    Tau Clearance in Alzheimer's: Brain Cells That Shuttle Toxic Protein

    Send us Fan Mail How does toxic Tau leave the brain? In this editorial, Vincent Prévot and colleagues spotlight tanycytes—specialized cells lining the third ventricle that shuttle Tau from cerebrospinal fluid into the blood. In Alzheimer's disease these cells are fragmented and their transport genes look dysregulated, which may worsen Tau buildup and open a new therapeutic angle. Source: Prévot V, Schwaninger M, Nogueiras R, Rasika S, Tau-ing and fro-ing: the tanycytic shuttle in neurodegeneration, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100643 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • September 28 · 20 min

    Brain Health as a Vital Sign: Lifestyle Steps Doctors Should Track

    Send us Fan Mail Should doctors check brain health the way they check blood pressure? In this editorial, neurologist Gregory Cooper looks at the Brain Health Vital Signs project, which scores patients on 15 lifestyle risk factors for dementia. He explains how the FINGER, US POINTER, and LatAm-FINGERS trials showed that exercise, diet, mental challenge, social connection, and heart health can protect thinking skills, and why clinics now need practical ways to help patients with memory problems follow that advice. Source: Cooper G, Is it time to make brain health a vital sign?, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100654 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • September 27 · 45 min

    Alzheimer's Brain Health Habits: Most Patients Skip the Guidelines

    Send us Fan Mail Even patients chasing new Alzheimer's antibody drugs often skip the lifestyle basics that protect the brain. A Brain Health Vital Signs study of 150 people with early Alzheimer's found fewer than 3% met all 15 consensus recommendations, with the biggest gaps in exercise, mood and stress, blood sugar, blood pressure, and weight. Those pursuing anti-amyloid therapy looked no better than those who were not. Source: Daffner KR, Riera K, Ghorayeb GR, McFeeley BM, Weizenbaum E, Willment K, Gale SA, Suboptimal adherence to brain health recommendations in patients pursuing anti-amyloid antibody therapy for Alzheimer's disease: Report from the Brain Health Vital Signs project, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100640 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • September 26 · 21 min

    Dementia Prevention Diet: Shanghai Diet vs MIND Diet, East Meets West

    Send us Fan Mail Most brain-healthy diet advice, like the Mediterranean and MIND diets, comes from studies of Western populations. In this editorial, Lei Feng of the National University of Singapore responds to a new review of diet and Alzheimer's risk across East and West. He highlights the Shanghai Cognitive Diet Pattern, which is built around what Chinese adults actually eat, and explains why whole dietary patterns tell us more than single nutrients. He also points to mixed trial results, including the MIND Diet Trial, which didn't beat its control diet, and argues for culturally adapted, personalized nutrition backed by long-term randomized trials. Source: Lei Feng, Dietary patterns for cognitive health: bridging evidence across east and west, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100663 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
Showing 21–40 of 67 episodes